|
Monday 19th April 2021 |
Text too small? |
Cannasouth Limited’s wholly owned subsidiary Cannasouth Bioscience Limited has received approval for an additional activity under its commercial Medicinal Cannabis Licence by the Medicinal Cannabis Agency (Agency) for its facilities based in Hamilton. The new supply activity is additional to existing cultivation and possession for manufacture activities on the license.
This licence means Cannasouth is ready to distribute its imported own brand products, once registered with the Agency. Cannasouth submitted its product assessment applications for its first three products to the Agency in November 2020.
Please see the link below for details:
2021-04-19 Supply Activity added to Cannasouth Commercial Licence
No comments yet
PEB - Pacific Edge Placement Increased to NZ$25.4 Million
Radius Care Reports Earnings Growth and 50% Higher Dividend
May 13th Morning Report
Pacific Edge launches capital raise of NZ$24 million
SML - Resignation of Synlait Director
FBU - Sale of Laminex Cheltenham property
CVT - Comvita Achieves Minimum Capital Raise Requirement
Devon Funds Morning Note - 04 May 2026
MEL - Meridian joins global ranks of sustainable companies
May 5th Morning Report